The American Heart Association (AHA) Scientific Sessions will be held in New Orleans, LA from 12–16 November 2016. This year's conference features a number of prominent data presentations. One late-breaking session on lipid trials features interesting new details from PCSK9 inhibitor studies, including atherosclerosis imaging from Repatha's (evolocumab; Amgen/Astellas) GLAGOV trial and extended dosing data from PCSK9si (The Medicines Company/Alnylam). New Phase III heart failure data for ularitide (Cardiorentis) are also highly anticipated. The data were supposed to be presented at the last American College of Cardiology meeting, but there were last-minute issues that the investigators wanted to fully validate. While Xarelto (rivaroxaban; Bayer/Johnson & Johnson) has struggled in the acute coronary syndrome indication, there will be new data on its use in patients undergoing percutaneous coronary intervention (PCI) who have atrial fibrillation, which could prove successful for the drug as it is being compared to vitamin K antagonists. On the device front, investigational device exemption (IDE) study data on HeartMate 3 (St. Jude Medical) versus HeartMate 2 will help determine if changes to the left-ventricular assist device (LVAD) have led to the hoped-for improvements. Drugs/Devices Highlighted:

• Dyslipidemia: Repatha (AMGN, Astellas), PCSK9si (MDCO, ALNY, ABUS), CSL112 (CSL Limited), MDCO 216 (MDCO, PFE), Evinacumab (REGN)


• Heart Failure: Ularitide (Cardiorentis, PDLI, Pharis), Injectafer (Daiichi, Galenica, Fresenius, Zeria), HeartMate 3 (STJ)


• Anticoagulation: Xarelto (BAYRY, JNJ), Pradaxa (Boehringer)


• Antiplatelet Therapy: Brilinta (AZN, MDCO)


• Cardiovascular Outcomes Trial in Type 2 Diabetes: Jardiance (Boehringer, LLY), Victoza (NVO)


• Cell Therapy: MarrowStim (ZBH)

To download the full conference planner in PDF, click the link at the top of the page. The support material includes a full Excel planner that allows you to select presentations/posters and then automatically create your own printable planner. It also includes potentially notable presentations/posters, primarily clinical, recommended by our analysts. If you have already selected presentations on the AHA itinerary planner and would like to format them like our Excel planner, please contact askanalyst@sagientresearch.com. For our disclosures, please read the Biomedtracker Research Standards.